Cytarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites